# CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

> **NCT03123783** · PHASE1,PHASE2 · COMPLETED · sponsor: **Apexigen America, Inc.** · enrollment: 140 (actual)

## Conditions studied

- Cancer
- Non Small Cell Lung Cancer Metastatic
- Metastatic Melanoma
- Neoplasm of Lung
- Melanoma

## Interventions

- **DRUG:** APX005M
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03123783
- **Lead sponsor:** Apexigen America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-10
- **Primary completion:** 2020-11-16
- **Final completion:** 2020-11-16
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2023-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123783, "CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03123783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*